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Abstract Chemotherapies active in preclinical studies
frequently fail in the clinic due to lack of efficacy, which
limits progress for rare cancers since only small numbers of
patients are available for clinical trials. Thus, a preclinical
drug development pipeline was developed to prioritize
potentially active regimens for pediatric brain tumors
spanning from in vitro drug screening, through intracranial
and intra-tumoral pharmacokinetics to in vivo efficacy
studies. Here, as an example of the pipeline, data are pre-
sented for the combination of 5-fluoro-20-deoxycytidine
and tetrahydrouridine in three pediatric brain tumor mod-
els. The in vitro activity of nine novel therapies was tested
against tumor spheres derived from faithful mouse models
of Group 3 medulloblastoma, ependymoma, and choroid
plexus carcinoma. Agents with the greatest in vitro potency
were then subjected to a comprehensive series of in vivo
pharmacokinetic (PK) and pharmacodynamic (PD) studies
culminating in preclinical efficacy trials in mice harboring
brain tumors. The nucleoside analog 5-fluoro-20-deoxycy-
tidine (FdCyd) markedly reduced the proliferation in vitro
of all three brain tumor cell types at nanomolar concen-
trations. Detailed intracranial PK studies confirmed that
systemically administered FdCyd exceeded concentrations
in brain tumors necessary to inhibit tumor cell prolifera-
tion, but no tumor displayed a significant in vivo thera-
peutic response. Despite promising in vitro activity and
in vivo PK properties, FdCyd is unlikely to be an effective
treatment of pediatric brain tumors, and therefore was
deprioritized for the clinic. Our comprehensive and inte-
grated preclinical drug development pipeline should reduce
the attrition of drugs in clinical trials.
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Introduction
Brain tumors are the most common pediatric solid tumors,
representing about 20 % of all childhood cancers. Treat-
ment of brain tumors presents a major clinical challenge
since the combination of neuro-surgery, radiation, and
chemotherapy should be balanced with the risk of longterm
neuroendocrine and neurocognitive side effects [1–4].
Medulloblastoma (MB), the most common malignant
childhood brain tumor, includes four subtypes [WNT,
SHH, Group 3 (G3), and G4], of which G3 has the worst
prognosis [5–8]. Ependymoma (EPs) and choroid plexus
carcinoma (CPCs) are less common and incurable in 40
and 70 % of cases, respectively [4, 9–11].
Conventional preclinical approaches to select drugs for
clinical trial led to mixed results, with many drugs failing
to reproduce in humans the anti-tumor activity observed in
animal models. To better select and assess potential new
therapies, we developed a series of mouse models that
closely recapitulate the morphology, gene expression pro-
file, and clinical behavior of MB [12–14], EP [9, 15], and
CPC [16]. With these mouse models we performed high
throughput drug screens (HTDS), in vivo pharmacokinetic
(PK) and efficacy studies, to identify new therapies to treat
children with brain tumors [2, 17, 18].
Recent whole genome sequencing studies of pediatric
brain tumors have identified few, recurrent oncogenic point
mutations targetable therapeutically [8, 9, 12]. Rather,
these tumors contain large chromosomal copy number
changes or aberrant epigenomes. Therefore epigenetic
regulators might provide attractive targets, since they may
re-establish normal gene expression profiles, including
those of tumor suppressors [19, 20]. We used a preclinical
drug development pipeline (Fig. 1) to evaluate compounds
that modulate the epigenome. Of the nine compounds
tested, the nucleoside analogue 5-fluoro-2-deoxycytidine
(FdCyd) showed the most activity in vitro. The results of
extensive PK studies optimized the dosing and scheduling
for preclinical efficacy studies. However, FdCyd co-ad-
ministered with THU failed to produce significant tumor
responses in vivo in each of the brain tumor models. Thus,
the use of the combination of FdCyd and THU was
deprioritized for the clinic providing an example of the
utility of our drug development pipeline.
Materials and methods
Tissue culture
Neurospheres were derived from the cerebella of Trp53-/-,
Cdkn2c-/- mice (also referred as p53p18NS) [21] and
from tumor cells from mouse G3 MBs (Myc 1 and Myc2)
[13]. TB-12-5950 is a G3MB patient-derived xenograft
(PDX) [18]. Ependymoma cells were generated and cul-
tured as previously described [9]. 2889 is a PDX of
ependymoma. CPC tumor cells were isolated from primary
tumors in Trp53LoxP, RBLoxP, PtenLoxP transgenic mice
[16]. Ink4a/Arf-/- neural stem cells were from the fore-
brain of E14.5 mouse embryos. The HEP G2, and BJ
fibroblasts lines identified compounds with nonspecific
toxicities [18]. (For more details see Supplementary
Material).
Library screen
In the Discovery Phase, the initial studies included the
screen of a library of 9 compounds against epigenetic
Fig. 1 High-throughput screening, pharmacokinetics, and preclinical
studies pipeline for pediatric brain tumors. Schematic drug pipeline to
bring compounds from discovery (molecular screen, in vitro func-
tional assays) to pre-clinical trials (PK and PD, efficacy studies) and
translation in the clinic (recommendation for Phase I). Nine
epigenetic compounds were tested in our pipeline. Only 5-fluoro-20-
deoxycytidine, our lead compound, performed successfully in all
assays leading up to in vivo efficacy studies
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regulators at a single concentration and a dose-response on
G3 MB, EP, and CPC tumor cells, as well as HEPG2 and
BJ (Fig. 1) [17, 18]. The library and dose response studies
are described in the Supplementary Material.
In vitro functional studies
Myc1 and Myc2 G3 MB, EP, and CPC tumor cells (Sup-
plementary Table 1) were plated in 96-well plates. After
24 h, 128 nL of a dilution series of a selected drug was
transferred creating a final drug concentration of
0.5–9.3 lM. To assess the optimal exposure time, the drug
was removed and replaced with fresh medium after 1, 3, 6,
10, 24, or 72 h (‘‘wash-out’’).
To test the effect of deoxycytidine on FdCyd efficacy,
EP cells were plated in 96 well plates. After 24 h, FdCyd
was added at final concentrations ranging from 0.1 nM to
50 lM alone or together with fixed concentration of
deoxycytidine (Sigma) of 0.0122, 0.195, 6.25 or 100 lM.
In both experiments, 72 h after drug addition to cells, we
added 100 lL of CellTiter-Glo reagent (Promega), and we
read the luminescence signal. Data analysis used GraphPad
Prism software (Version 5.04).
In vivo pharmacokinetic studies
Once a drug passed the Discovery Phase it was moved to
the Pre-Clinical Phase, which included PK and PD studies
(Fig. 1). The details of the plasma PK and cerebral
microdialysis studies are provided in the Supplemental
Materials.
In vivo efficacy studies
Efficacy studies (Fig. 1) were performed in G3 MB
(Myc1), EP (915 RTBDN), and CPC (CPC300) cells co-
expressing luciferase and yellow fluorescent protein (YFP)
(vCL20SF2-Luc2aYFP). Drugs were injected post-tumor
implant, after 4 days (G3 MB and EP), and 7 days (CPC).
Tumor growth was monitored by bioluminescence imaging
twice weekly. Complete blood counts, serum chemistries,
and body weight were monitored in mice throughout
therapy. Mice showing signs of morbidity, including head
dome, slow motion, seizure, or toxicity ([20 % weight
loss) were euthanized and tumors removed: one portion
was fixed in 10 % formalin for histopathology and the
other flash-frozen for molecular analysis. For more details,
see Supplementary Material.
In vitro and in vivo pharmacodynamic studies
To assess whether FdCyd/THU was cytotoxic or cytostatic,
pharmacodynamic studies were performed on mouse G3
MB. G3 MB cells were plated and drugs added at their
EC50. Cells were collected at 24, 48, and 72 h after drug
addition and analyzed by fluorescence-activated cell sort-
ing (FACS). Annexin V staining evaluated apoptosis, and
DAPI staining DNA integrity. For proliferation analysis,
cells were treated with FdCyd at the EC50 for 22 h and
incubated with BrdU for an additional 2 h. Cells were
analyzed for DNA content by FACS. To assess apoptosis
and proliferation in vivo, G3 MB, EP, and CPC tumors
were isolated from mice 3, 8, or 24 h after treatment with
compound or vehicle, fixed in 10 % formalin, and sections
were immunostained with antibodies to Caspase 3 (apop-
tosis) or Ki67 (proliferation). See Supplementary Material
for more details.
DNA methylation
DNA was extracted from mouse G3 MB neurospheres and
tumors after DMSO or FdCyd and THU administration
according to the manufacturer’s recommendation (Epi-
gentek, P-1018). Global DNA methylation of 100 ng of
DNA was measured by using a colorimetric kit that mea-
sures the level of 5-methylcytosine in an ELISA-like,
microplate-based format (Epigentek, P-1034).
Results
FdCyd suppresses the in vitro proliferation of G3
MB, EP, and CPC neurosphere lines
We tested the in vitro growth inhibition of nine epigenetic
regulators against tumorspheres derived from murine
G3 MB, EP, and CPC (Supplementary Table 2). We
identified FdCyd as a highly effective inhibitor of prolif-
eration of all three tumor cell types, with 72-hr EC50 values
from 1 to 6 nM (Fig. 2a). FdCyd also efficiently sup-
pressed the proliferation of tumor cells from PDXs of G3
MB and EP (Fig. 2b).
To assess anti-tumor selectivity, FdCyd growth inhibi-
tion assays were performed in several mouse and human
cell lines (Fig. 2c). Trp53-/-, Cdkn2c-/- neurospheres and
Ink4a/Arf-/- neural stem cells showed sensitivity to
FdCyd, but not BJ and HEPG2 cells. EC50 values of
additional mouse G3 MB and EP neurosphere lines dis-
played similar EC50 to those used in the primary screen
(Supplementary Fig. 1A).
Because FdCyd had low EC50 values in mouse tumors
with a good therapeutic index, it was chosen for in vitro
functional studies that determined the concentration–time
exposure of FdCyd required to suppress proliferation of
G3 MB, EP, and CPC neurospheres. After 1 h FdCyd
exposure, EC50 values were 8 ± 2 nM for G3 MB,
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22 ± 8 nM for EP and 63 ± 28 nM for CPC (Fig. 2d).
The remaining time points, showed that longer exposure to
the drug decreased EC50 values as expected to low
nanomolar: 5, 4, 2.3, and 1 nM (G3 MB, left panel), 17, 13,
3, and 0.7 nM (EP, middle panel) and 58, 44, 31, and 1 nM
(CPC, right panel) (Supplementary Fig. 1B). To address
whether the levels of deoxycytidine kinase (dCK) were
sufficient to convert FdCyd to its active form, we added
various concentrations of deoxycytidine, the endogenous
substrate of dCK [22], to our cell culture media in com-
bination with FdCyd and compared EC50 s to FdCyd alone
(Fig. 2e). We found that 100 lM deoxycytidine in com-
bination with FdCyd induced a shift in EC50 from 0.05 to
0.69 lM. In contrast, lower concentrations of deoxycy-
tidine from 0.0122 up to 6.26 lM did not induce a dramatic
shift in EC50 s.
FdCyd is a potent cytotoxic agent [23] and a DNA
methyltransferase (DNMT) inhibitor in vitro [24]. In vivo,
FdCyd is converted by cytidine deaminase into 5-fluoro-2-
deoxyuridylate which impairs FdCyd-mediated DNMT
inhibition [25]. To prevent the metabolism of FdCyd into
its metabolites, a cytidine deaminase inhibitor, 3,4,5,6-te-
trahydrouridine (THU) can be co-administered [25]. Full
dose–response synergy experiments of THU and FdCyd
against G3 MB neurospheres showed no antagonism
between the two drugs, identifying FdCyd as the main
active form in vitro (Supplementary Fig. 1C).
Plasma pharmacokinetics and tumor extracellular
fluid disposition of FdCyd
FdCyd plasma PK administered with THU was studied in
non–tumor-bearing CD1 nude mice at a dosage of 25 mg/
kg formulated with THU (100 mg/kg) [24] delivered either
IV (Fig. 3a) or IP (Fig. 3b). FdCyd plasma concentration–
time data were represented by a 1-compartment model
(Fig. 3c). The limited plasma sampling time points derived
by using a D-optimality method were 0.25, 1, and 4 h. The
mean ± SD of individual plasma exposure (AUC0-Inf) of
FdCyd in non–tumor-bearing CD1 nude mice after FdCyd
(25 mg/kg) was 113.75 ± 4.77 lM*h after IV adminis-
tration and 111.92 ± 6.55 lM*h after IP administration.
Limited published clinical PK data suggested that FdCyd
exposure in CD1 nude mice dosed at 25 mg/kg was
approximately 4 times higher than that in humans given the
recommended Phase II dosage (RP2D) of 100 mg/m2 [26].
Thus, assuming linear PK in mice, we reduced our IP
mouse dosage to a more clinically relevant regimen of
6 mg/kg FdCyd in combination with 100 mg/kg THU. A
confirmatory PK study (n = 3, 3 time points per mouse),
showed that the murine plasma exposure at this dosage was
comparable to that estimated for the RP2D of FdCyd in
humans. For subsequent microdialysis and efficacy studies,
we used a FdCyd dosage of 6 mg/kg combined with
100 mg/kg THU.
We conducted individual cerebral microdialysis studies
to assess FdCyd tECF disposition in CD1 nude mice
bearing cortical implants of mouse G3 MB, EP, or CPC
tumors (Fig. 3d). Population-based PK modeling derived
individual plasma and tECF concentration–time profiles for
each animal (Fig. 3c). FdCyd was negligibly bound to
plasma protein (fu,p * 1) and brain homogenate (fu,b * 1)
in vitro (data not shown). FdCyd tECF concentrations were
above in vitro 1-h IC50 values for at least 3 h in all mouse
tumor models, suggesting sufficient FdCyd exposure in the
brain to inhibit tumor growth in vivo (Fig. 3d).
FdCyd is ineffective in suppressing G3 MB, EP,
and CPC tumor growth in vivo
To determine if FdCyd was efficacious in vivo, mice were
orthotopically implanted with luciferase-expressing mouse
G3 MB, EP, or CPC tumorspheres. FdCyd dosing was
modeled using our PK data that identified tECF
Fig. 2 In vitro dose–response for FdCyd. Cells were plated at day 0.
FdCyd was added in doses ranging from 1 to 10 lM at day 1;
CellTiter-Glo assay results were read at day 3. aMouse G3 MB Myc1
neurospheres EC50 = 1.7 nM (orange curve), mouse EP neuro-
spheres EC50 = 4 nM (green curve), and mouse CPC neurospheres
EC50 = 5.6 nM (blue curve); b Patient-derived xenografts of a
human G3 medulloblastoma, TB-12-5950 EC50 = 1 nM (orange
curve), and a human EP EC50 = 8.3 nM (green curve); c Trp53
-/-,
Cdkn2c-/- neurospheres (purple curve), Ink4Arf-/- neural stem cells
(green curve), BJ (red curve), and HEPG2 (blue curve) control cells.
d 1 h FdCyd wash-out experiment in G3 MB (Myc1) (orange curve),
EP (green curve), and CPC (blue curve) cells. e 72 h exposure in EP
cells with increasing concentrations ranging from 0.1 to 50 lM of
FdCyd alone (green) or with various fixed concentration of deoxy-
cytidine: 100 lM (dark red); 6.25 lM (red); 0.195 lM (pink);
0.0122 lM (blush pink)
228 J Neurooncol (2016) 126:225–234
123
concentrations above in vitro 1-h IC50 values in all tumor
models when FdCyd was administered at 6 mg/kg together
with 100 mg/kg THU. Dose scheduling was modeled on
the clinical trial—NCT00978250, administered as a 5 days
treatment followed by 2 days off for 2 weeks for a 4-week
cycle. IV injections of FdCyd and THU did not decrease
the luminescence signal of animals implanted with G3 MB
(Fig. 4a, left panel), EP (Fig. 4a, middle panel) or CPC
(Fig. 4a, right panel). Mice bearing mouse G3 MB had no
increased survival when given IV FdCyd and THU com-
pared to vehicle-treated animals, 19 versus 20 days,
respectively (Fig. 4b). Mice bearing mouse EP or CPC
(Fig. 4b) that received vehicle had a median survival of 22
and 30 days, respectively, but FdCyd and THU-treated
mice had a median survival of 22 and 28 days, respec-
tively. Some treated animals developed severe gut toxicity,
manifested by diarrhea, and subsequent massive weight
loss (11–18 %), requiring euthanasia before the end of the
second treatment week in all 3 models (Fig. 4c). Complete
blood counts including white blood cells, neutrophils, and
platelets were performed on mouse G3 MB-bearing mice
treated IV (Supplementary Fig. 2A) and on mouse EP-
bearing mice treated IV (Supplementary Fig. 2B). No
significant myelosuppression was observed.
In vitro and in vivo FdCyd pharmacodynamic
studies
To determine the mechanism by which FdCyd inhibited
tumorsphere proliferation in vitro, we tested the effect of a
3-day drug exposure on Myc1 and Myc2, and Trp53-/-,
Cdkn2c-/- neurospheres. Treatment of mouse G3 MB
tumorspheres with FdCyd alone increased the number of
cells in the G0/G1phase of the cell cycle (Fig. 5a) and the
number of apoptotic cells (Fig. 5b) compared to DMSO-
treated cells without affecting control neurospheres. We
could not detect changes in total DNA methylation after a
3-day in vitro treatment with FdCyd (4 nM) and THU
(10 lM), measured by the percentage of 5-methyl-cytosine
(Fig. 5c).
To assess why FdCyd proved ineffective in vivo, we
used immunohistochemistry (IHC) to test if exposure to the
drug impacted in vivo cell proliferation (Fig. 5d; Supple-
mentary Table 3) or apoptosis (Fig. 5e; Supplementary
Table 4), at 3, 8, or 24 h post-treatment with either vehicle
or FdCyd and THU. Representative images for all three
mouse tumor types showed Ki67 (Fig. 5d) and Caspase-3
(Fig. 5e) staining 3 h after treatment with vehicle or FdCyd
and THU (all time points in Supplementary Fig. 3). Mouse
Fig. 3 Plasma and tECF disposition of FdCyd. Full plasma pharma-
cokinetic study: unbound FdCyd concentrations in plasma are plotted
against time for a IV and b IP administrations (open circles represents
observed concentrations, solid line represents model-predicted pop-
ulation mean concentrations). c Schematic of pharmacokinetic model
fitted to microdialysis and full plasma pharmacokinetic study results
(Ka: absorption rate constant after IP injection; CL: systemic
clearance; CL23 and CL32: influx and efflux clearance for tECF
compartment; VC and VT: volume of central and tECF compartment).
Cerebral microdialysis study: Unbound FdCyd concentrations in
plasma and tECF plotted against time for CD1 nude mice bearing
orthotopic d G3 MB, EP, or CPC tumors (red open circle and solid
line represent observed and population mean concentrations of
unbound FdCyd in plasma, respectively; blue open circle and solid
line represent observed and population mean concentrations of
unbound FdCyd in tECF, respectively; green dotted line represents
in vitro 1 h IC50 in respective tumor model)
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G3 MB showed significant differences (p = 0.0022)
between treated and untreated mice at 3 h, but this effect
was lost over time. In vivo, we found no significant dif-
ference in the percentage of 5-methyl-cytosine in tumors
from G3 MB-bearing animals vehicle-treated versus those
treated with FdCyd and THU (Fig. 5f).
Discussion
For a quarter of a century, no new drugs have been
approved by the US Food and Drug Administration to treat
children with brain tumors. The overall success rate in
developing new agents from preclinical models to clinical
cancer trials is less than 8 % [27]. To find new therapies,
we used accurate mouse models of pediatric brain tumors
that morphologically and transcriptionally recapitulate the
human diseases. We devised a preclinical drug pipeline
combining in vitro and in vivo screens focusing on
epigenetic regulators. One of the key features of this
pipeline was the early integration of toxicity in vitro
through comparative studies with mouse neurospheres and
embryonic neural stem cells, human HEP G2 and BJ cells.
Despite activity against the neural stem cell population
in vitro, no obvious neuro-toxicity was observed in vivo.
We found that the pyrimidine analog FdCyd suppressed
proliferation of all three tumor models in vitro. To use the
most clinically relevant dosing regimen in preclinical
studies, we performed rigorous plasma PK studies to assess
FdCyd exposure in murine plasma. Since the plasma
FdCyd AUC at our initial dosage (25 mg/kg) exceeded that
reported for the recommended Phase II human dosage [28],
we reduced the FdCyd dosage to 6 mg/kg. Using dosages
that are associated with clinically relevant plasma systemic
exposures is critical because many preclinical studies show
antitumor effects, but at supra-pharmacologic concentra-
tions, and, by inference, systemic exposure that cannot be
achieved safely in patients. In addition, one-quarter of
Fig. 4 In vivo treatment of G3 MB-, EP-, and CPC-bearing mice
with FdCyd and THU. a Fold-increase in bioluminescence signal of
the brain of G3 MB-bearing mice (n = 10 for FdCyd/THU-treated
animals; n = 5 for vehicle-treated animals), EP-bearing mice
(n = 9 for FdCyd/THU-treated animals; n = 9 for vehicle-treated
animals), and CPC-bearing mice (n = 9 for FdCyd/THU-treated
animals; n = 9 for vehicle-treated animals). All animals were treated
on days 5 through 9 and 12 through 16 after tumor implant with
FdCyd (6 mg/kg) and THU (100 mg/kg) administered IV in a 200 lL
volume of 5 % dextrose or with 200 lL of 5 % dextrose. b Survival
curves for vehicle-treated animals (black) and FdCyd/THU-treated
mice (orange): G3 MB-bearing mice, EP-bearing animals, or CPC-
bearing animals all treated IV. c Body weight measurement in control
(black) or treated animals (orange) for G3 MB, EP, and CPC
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molecules entering clinical trials fail due to pharmacolog-
ical issues including the lack of absorption or penetration
into the target organ [26, 27, 29]. We performed micro-
dialysis studies to document adequate tECF exposure.
Using a clinically relevant dosage and schedule, we saw no
significant tumor inhibition in our tumor models. The
FdCyd dosage and schedule was based upon the pre-
sumption that we would see activity in our models to
rapidly move FdCyd into clinical trials for children with
brain tumors. We were prevented from evaluating alter-
native schedules due to toxicities observed with our initial
regimen.
FdCyd integrates into chromatin, inhibits DNA methy-
lation and induces G2/M arrest in colon cancer cell lines
[30]. In contrast, FdCyd induced G0/G1 arrest in vitro in
the three mouse models, consistent with a report that
suggests DNA-damaging agents can cause either G1- or
G2-phase cell-cycle arrest [31]. We predicted that the
FdCyd’s metabolite 5-FU [24] would lead to apoptosis, as
shown in a previous ependymoma study [17]. We detected
a significant increase in apoptosis in vitro after 48 h of
treatment with FdCyd but only a slight, significant increase
after 3 h in vivo in G3 MB. We found small, but not sig-
nificant, increase of apoptosis in the CPC model, while at
all other time points, we saw no difference between treated
and untreated mice. None of the models treated with
FdCyd and THU showed changes in proliferation. Since we
did not see any cytotoxic effect in vivo compared to
in vitro, the question remains whether the cytotoxic effect
was insufficient to alter Caspase3 or Ki67 levels in vivo.
Much insight has been gained into the relevance and
function of histone methylation-dependent epigenetic
events in G3 MB [32] and EP [33], while little is known for
CPC. Despite FdCyd’s ability to bind DNA methyltrans-
ferases and prevent DNA methylation [34], FdCyd and
THU did not affect global DNA methylation in vitro or
in vivo in mouse G3 MBs.
Ki67 and Caspase3 results highlight the difference
between in vivo and in vitro cell behavior. Even though
neurospheres, when implanted into the cortex of naive
animals, recapitulate the primary tumors, the transcriptome
and methylome of cells in culture might be different from
those in vivo. Indeed, multiple studies have already
addressed these differences [35]. Therefore, drug screening
should be based on multiple cell lines and integrate a
validation cohort of independently-derived tumors, as well
as primary patient-derived xenografts, when available.
Moving forward, it will be important to integrate
Fig. 5 In vitro and in vivo pharmacodynamics studies. a, b In vitro:
Trp53-/-, Cdkn2c-/- neurospheres and Myc1 and Myc2 G3 MB
tumor spheres were untreated (black lines) or treated with 4 nM
FdCyd (orange lines) and analyzed for a proliferation by BrdU
analysis 24 h after treatment (1 G0/G1 phase, 2 S phase, 3 M phase)
and b apoptosis by Annexin V and DAPI staining 24, 48, and 72 h
after treatment. c In vitro: Trp53-/-, Cdkn2c-/- neurospheres and
Myc1, Myc2, Myc3 G3 MB tumor spheres were left untreated (black
bars) or treated with 4 nM FdCyd and 10 lM THU for 72 h (orange
bars) and analyzed for total DNA methylation (% 5-methyl-cytosine).
d In vivo: sections of tumors from mice transplanted with G3 MB,
EP, or CPC tumor spheres; stained with antibodies for Ki67 and
Caspase 3 and harvested at 3, 8, or 24 h after vehicle or FdCyd and
THU treatment. Representative image of d Ki67 and e Caspase-3
stains in all three tumor models at 3 h time point. Control depicted in
upper panel and FdCyd ? THU treated animals depicted in lower
panel. f Global DNA methylation in 3 independently-derived mouse
G3 MBs from mice left untreated (black bars) or treated with FdCyd
and THU (orange bars)
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pharmacodynamic measurements and potentially assess the
mechanism of cell death in vitro as early as possible.
The lack of in vivo efficacy may be explained by
chemoresistance that could be due to tumor cell-intrinsic
changes [36], extrinsic factors such as cytokines and
growth factors [37] emphasizing the importance of the
tumor microenvironment, especially the presence of tumor-
associated macrophages that could play a critical role in
drug resistance [38]. Combination studies with epigenetic
compounds may be a better therapeutic strategy than sin-
gle-arm studies. Many new epigenetic drugs may offer
synergistic benefits and synergize with conventional ther-
apies [39].
Another valid hypothesis was that the lack of FdCyd
efficacy in vivo might have been due to competition with
deoxycytidine, the endogenous substrate of deoxycytidine
kinase [22] since deoxycytidine is required to convert
FdCyd into its active prodrug (FdCyd triphosphate) [24].
We found that only high levels (100 40]. Therefore, we
conclude that it is unlikely that deoxycytidine concentra-
tions reached levels high enough to affect FdCyd activation
in our in vivo experiments.
Our studies highlight the importance of in vitro toxicity
studies in combination with detailed PK and PD studies to
identify drugs for use in the clinic and to avoid taking a
drug forward that looks feasible in in vitro screens but for
which efficacy does not translate into an in vivo setting. By
testing multiple tumor model systems, including faithful
mouse models and PDXs, we reduced the effects of bias
and provided a more reliable readout. Using this approach,
we recently identified an inhibitor of the ABC transporter
ABCG2 to be efficacious in increasing survival of G3 MB-
bearing mice [41], demonstrating that this pipeline allows
the identification of novel therapies. Therefore, we propose
to implement our preclinical screening pipeline as a stan-
dard of practice. In the future, candidate compounds will be
tested in pre-clinical studies in tumor-bearing animals in a
more clinically relevant setting by their integration with
resection followed by radiation and standard-of-care
chemotherapy.
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